Latest Industry Insights

Earlier this year, researchers reported in Annals of Oncology that they had developed a blood test that was able to detect, with 99.3% specificity, more than 50 types of cancer and identify exactly where in the body the cancer had originated – in some cases before any symptoms of the disease had manifested. We spoke to the study’s corresponding author, Michael V. Seiden MD PhD, to learn more.

Technology Networks spoke with Rohan Thakur, Executive Vice President of Life Sciences Mass Spectrometry at Bruker Daltonics, to discuss the company's latest analytical technologies and their capabilities.

With advances in cellular and tissue-based imaging, researchers are able to peel back the layers on new challenges and test hypotheses to solve more problems. We heard about some of the advancements being made in the field of confocal microscopy.

Technology Networks recently spoke with Mike Sherman, Chief Executive Officer at Chimerix to learn more about the company’s oncology, biodefense and COVID-19 therapeutic efforts.

Technology Networks recently had the pleasure of speaking to Dr Sandeep “Bobby” Reddy, Chief Medical Officer of NantHealth to gain a better understanding of the impact COVID-19 is having on the treatment of cancer. Reddy discusses what is currently known, in terms of risk and severity of SARS-CoV-2 infection in individuals with cancer, and elaborates on the innovative approaches that have been adopted by oncologists to enable continuation of high-quality care during the pandemic.

The UK registered and self-funding charity LifeArc has several antibody–drug conjugate (ADC) programs in the oncology and non-oncology space. Technology Networks recently had the pleasure of speaking with Dr Laura Murch, Scientist at LifeArc, to learn more about ADCs. She highlights some of the antibody characterization assays they have developed to identify candidate ADCs, and touches on the regulatory success of ADCs.

Jagannath Swaminathan is the co-founder of Erisyon and a researcher at the Marcotte Lab at the University of Texas Austin. In this interview, we discuss the concept of next-generation protein sequencing, clinical proteomics and the critical role of protein sequencing in the fight against COVID-19.

Technology Networks recently spoke with Martin Butzal, Head of Medical Europe at bluebird bio, to learn more about the exciting developments and key trends in the gene therapy space.

Technology Networks recently spoke with three of the leaders in the cell and gene therapy space, Allogene Therapeutics, bluebird Bio and Mogrify to gain their insights on the next developments in this space.

Technology Networks recently spoke with Gary Kruppa, PhD, Vice President of Proteomics, Bruker Daltonics Inc., to learn more about the advancing research area immunopeptidomics, and to discuss the current status of single cell proteomics.